Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a phase Ⅱ trial of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.
Condition or disease
Drug: gemcitabine, cisplatin, capecitabine
The main purpose of this study is to evaluate the efficacy and safety of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
unresectable locally advanced pancreatic cancer
no distant metastasis
histologically confirmed adenocarcinoma of pancreas
18-75 of age
ECOG performance status 0-2
normal marrow function :
WBC at least 3,000/mm3 OR Absolute neutrophil count at least 1,500/mm3
Platelet count at least 100,000/mm3
normal liver function :
--Bilirubin no greater than 2.0 mg/dL AST less than 3 times upper limit of normal (ULN)
Keywords provided by Seoul National University Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Digestive System Neoplasms Neoplasms by Site Neoplasms
Endocrine Gland Neoplasms Pancreatic Diseases
Digestive System Diseases
Endocrine System Diseases